Pierre-Yves Scarabin studied medicine in University of Rennes and then he obtained a Master of Epidemiology at the University of Paris XI. He is a research director at the National Institute of Health and Medical Research (Inserm). In 1983 he participated in the creation of the Cardiovascular Epidemiology Inserm Unit 258 located at the Broussais Hospital in Paris. Since 1st January 2006, Pierre-Yves Scarabin coordinates the Hormones and Cardiovascular Disease team which is now part of the Center of Epidemiology and Population Health (Inserm UMR-S 1018) at Villejuif.
Main research area of Pierre-Yves Scarabin focuses on the thrombotic component of cardiovascular disease. Notably, he showed that an increased fibrinogen level was an important risk factor for myocardial infarction in men. In addition, he studied the effects of both estrogens and progestogens on thrombotic process among premenopausal women (oral contraceptive, pregnancy, ovarian stimulation syndrome) and postmenopausal women (hormone therapy, endogenous hormones). Above all, he demonstrated the importance of the route of estrogen administration in blood coagulation activation among postmenopausal women using hormone therapy. Pierre-Yves Scarabin is the principal investigator of several surveys including the ESTHER study which showed for the first time the safety of transdermal estrogens with respect to thrombotic risk among postmenopausal women.